| Literature DB >> 31571835 |
Yong-Liang Zhu1, Shuang-Long Li1, Ke-Li Chen1, Kun-Peng Ma1, De-Qian Wu1, Xiang-Jun Qiu1.
Abstract
OBJECTIVE: To investigate the effects of Chinese herb Danzhi Xiaoyao pills on the pharmacokinetics of venlafaxine and its metabolites O-desmethylvenlafaxine (ODV) and N-desmethylvenlafaxine (NDV) in beagles by using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).Entities:
Keywords: Danzhi Xiaoyao pills; NDV; ODV; UPLC-MS/MS; beagle; drug–drug interaction; venlafaxine
Mesh:
Substances:
Year: 2019 PMID: 31571835 PMCID: PMC6759287 DOI: 10.2147/DDDT.S221927
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Figure 1The chemical structure of venlafaxine (A), ODV (B), NDV (C), diazepam (D).
Figure 2Information of components in Danzhi Xiaoyao pill (DZXY). (A) Figures of herbs in DZXY. (B) Ratio of each herb in DZXY. (C) List of accepted Botanical, Herbal and Chinese name of the corresponding herb in DZXY according to .
Figure 3Chromatograms of venlafaxine and its metabolite. (A) Blank plasma; (B) blank plasma spiked with venlafaxine, ODV, NDV and internal standard; (C) beagle sample.
Precision And Accuracy Of Venlafaxine, ODV And NDV In Beagle Plasma (n = 6, Mean±SD)
| Analytes | Added (ng/mL) | Intra-Day Precision | Inter-Day Precision | ||||
|---|---|---|---|---|---|---|---|
| Detected (ng/mL) | RSD(%) | RE(%) | Detected (ng/mL) | RSD(%) | RE(%) | ||
| Venlafaxine | 2.5 | 2.42±0.17 | 6.87 | −3.07 | 2.42±0.13 | 5.23 | −3.07 |
| 100 | 98.94±6.73 | 6.80 | −1.06 | 99.94±1.92 | 1.92 | −0.06 | |
| 1500 | 1498.87±14.54 | 0.97 | −0.08 | 1503.00±8.54 | 0.57 | 0.20 | |
| ODV | 2.5 | 2.49±0.14 | 5.59 | −0.40 | 2.47±0.08 | 3.10 | −1.12 |
| 100 | 100.65±0.97 | 0.96 | 0.65 | 101.42±0.51 | 0.51 | 1.42 | |
| 1500 | 1501.75±6.81 | 0.45 | 0.12 | 1495.23±7.46 | 0.50 | −0.32 | |
| NDV | 0.25 | 0.25±0.01 | 2.97 | −0.53 | 0.24±0.01 | 4.53 | −5.24 |
| 10 | 10.32±0.48 | 4.66 | 3.20 | 10.07±0.25 | 2.50 | 0.69 | |
| 150 | 152.29±3.66 | 2.40 | 1.53 | 150.71±1.59 | 1.05 | 0.47 | |
Recovery And Matrix Effects For Venlafaxine, ODV, NDV And IS Of Quality Control Samples In Beagle Plasma (n = 6, Mean±SD)
| Analytes | Added (ng/mL) | Recovery (%) | ME(%) | ||
|---|---|---|---|---|---|
| Detected (ng/mL) | RSD(%) | Detected (ng/mL) | RSD(%) | ||
| Venlafaxine | 2.5 | 85.76 ± 2.64 | 3.08 | 100.94± 4.45 | 4.40 |
| 100 | 84.47± 4.30 | 5.09 | 101.53 ± 3.01 | 2.96 | |
| 1500 | 80.53 ± 2.39 | 2.97 | 99.49 ± 2.21 | 2.22 | |
| ODV | 2.5 | 87.43±4.90 | 5.60 | 101.30±4.32 | 4.18 |
| 100 | 84.92±3.62 | 4.26 | 99.83±3.67 | 3.67 | |
| 1500 | 98.48±2.96 | 3.00 | 98.91±2.46 | 2.49 | |
| NDV | 0.25 | 83.45±4.18 | 5.01 | 99.49 ±4.15 | 4.17 |
| 10 | 81.66 ±3.85 | 4.72 | 101.88 ±3.11 | 3.06 | |
| 150 | 85.24 ±2.56 | 3.01 | 99.83 ±2.53 | 2.53 | |
| IS | 50 | 91.03 ±5.88 | 6.46 | 100.10 ± 3.69 | 3.68 |
Stability For Venlafaxine In 4 Different Storage And Temperature Conditions (n = 6, Mean±SD)
| Storage Conditions | Added (ng/mL) | Detected (ng/mL) | RSD(%) | RE(%) |
|---|---|---|---|---|
| Room temperature,4hrs | 2.5 | 2.54 ± 0.17 | 6.54 | 1.40 |
| 100 | 98.15±2.72 | 2.77 | –1.85 | |
| 1500 | 1512.03±41.36 | 2.74 | 0.80 | |
| 4 °C, 24 hrs | 2.5 | 2.48 ± 0.15 | 6.15 | −0.80 |
| 100 | 102.08 ± 4.28 | 4.20 | 2.08 | |
| 1500 | 1490.78 ±38.56 | 2.59 | –0.61 | |
| Three freeze–thaw cycles | 2.5 | 2.35 ± 0.15 | 6.23 | −5.87 |
| 100 | 101.46 ± 5.30 | 5.22 | 1.46 | |
| 1500 | 1479.61 ±46.91 | 3.17 | –1.36 | |
| –20°C,4 weeks | 2.5 | 2.30 ± 0.12 | 5.05 | −8.13 |
| 100 | 96.35 ± 2.60 | 2.70 | –3.65 | |
| 1500 | 1468.51 ±36.93 | 2.52 | -2.10 |
Stability For NDV In 4 Different Storage And Temperature Conditions (n = 6, Mean±SD)
| Storage Conditions | Added (ng/mL) | Detected (ng/mL) | RSD(%) | RE(%) |
|---|---|---|---|---|
| Room temperature,4hrs | 0.25 | 0.25 ± 0.02 | 6.65 | −2.00 |
| 10 | 9.54±0.40 | 4.17 | –4.62 | |
| 150 | 150.23±7.45 | 4.96 | 0.16 | |
| 4 °C, 24 hrs | 0.25 | 0.24 ± 0.01 | 5.04 | −3.47 |
| 10 | 10.28 ± 0.51 | 4.93 | 2.76 | |
| 150 | 148.52 ± 6.18 | 4.16 | –0.99 | |
| Three freeze–thaw cycles | 0.25 | 0.25 ± 0.01 | 5.87 | −0.67 |
| 10 | 9.74± 0.80 | 8.18 | –2.58 | |
| 150 | 148.33 ± 9.07 | 6.12 | -1.12 | |
| –20°C,4 weeks | 0.25 | 0.25± 0.02 | 7.16 | −0.73 |
| 10 | 10.30 ±0.71 | 6.93 | 3.62 | |
| 150 | 147.79 ±5.35 | 3.62 | –1.47 |
Figure 4Mean plasma concentration–time curves of venlafaxine after oral administration of 10.28 mg/kg venlafaxine hydrochloride tablets in beagles (n = 6, mean±SD).
Figure 5Mean plasma concentration–time curves of ODV after oral administration of 10.28 mg/kg venlafaxine hydrochloride tablets in beagles (n = 6, mean±SD).
Figure 6Mean plasma concentration–time curves of NDV after oral administration of 10.28 mg/kg venlafaxine hydrochloride tablets in beagles (n = 6, mean±SD).
Pharmacokinetic Parameters Of Venlafaxine After Oral Administration Of 10.28 mg/kg Venlafaxine In Beagles (n = 6, Mean±SD)
| Parameters | Control Groups | Experimental Groups |
|---|---|---|
| t1/2 (hrs) | 4.35 ± 0.82 | 3.27 ± 0.63* |
| Tmax (hrs) | 0.97 ± 0.30 | 1.42 ± 0.49** |
| MRT(0-t) (hrs) | 6.16 ± 0.96 | 5.14 ± 1.22 |
| MRT(0-∞) (hrs) | 6.29 ± 1.08 | 5.17 ± 1.24 |
| Cmax (ng/mL) | 2267.26 ± 252.89 | 1542.64 ± 190.73* |
| CLz/F (L/h/kg) | 0.76 ± 0.22 | 1.32 ± 0.31** |
| AUC(0-t) (ng·h/mL) | 13,875.79 ± 3569.69 | 7993.16 ± 2157.76** |
| AUC(0-∞) (ng·h/mL) | 13,934.79 ± 3609.23 | 8001.91 ± 2167.58** |
Notes: Compared with venlafaxine group: *P<0.05, **P<0.01.
Pharmacokinetic Parameters Of NDV After Oral Administration Of 10.28 mg/kg Venlafaxine In Beagles (n = 6, Mean±SD)
| Parameters | Control Groups | Experimental Groups |
|---|---|---|
| t1/2 (hrs) | 4.07±0.88 | 4.75±1.52 |
| Tmax (hrs) | 0.73±0.14 | 1.03±0.27** |
| MRT(0-t) (hrs) | 4.06±0.44 | 4.15±0.75 |
| MRT(0-∞) (hrs) | 4.35±0.53 | 4.75±1.21 |
| Cmax (ng/mL) | 50.98±5.76 | 58.74±12.33 |
| CLz/F (L/h/kg) | 57.45±10.35 | 47.27±10.10 |
| AUC(0-t) (ng·h/mL) | 177.36±34.78 | 216.22±51.85* |
| AUC(0-∞) (ng·h/mL) | 179.26±34.94 | 220.68±51.41* |
Notes: Compared with venlafaxine group: *P<0.05, **P<0.01.
Stability For ODV In 4 Different Storage And Temperature Conditions (n = 6, Mean±SD)
| Storage Conditions | Added (ng/mL) | Detected (ng/mL) | RSD(%) | RE(%) |
|---|---|---|---|---|
| Room temperature,4hrs | 2.5 | 2.54 ± 0.07 | 2.95 | 1.53 |
| 100 | 100.86±2.41 | 2.39 | 0.86 | |
| 1500 | 1504.01±11.07 | 0.74 | 0.27 | |
| 4 °C, 24 hrs | 2.5 | 2.56 ± 0.09 | 3.42 | 2.27 |
| 100 | 102.07 ± 5.81 | 5.69 | 2.07 | |
| 1500 | 1493.00 ± 25.55 | 1.71 | –0.47 | |
| Three freeze–thaw cycles | 2.5 | 2.56 ± 0.14 | 5.31 | 2.47 |
| 100 | 95.60 ± 3.89 | 4.07 | –4.40 | |
| 1500 | 1503.85 ± 11.20 | 0.75 | 0.26 | |
| –20°C,4 weeks | 2.5 | 2.61 ± 0.15 | 5.81 | 4.27 |
| 100 | 102.61 ± 5.28 | 5.15 | 2.61 | |
| 1500 | 1490.73 ± 20.42 | 1.37 | –0.62 |
Pharmacokinetic Parameters Of ODV After Oral Administration Of 10.28 mg/kg Venlafaxine In Beagles (n = 6, Mean±SD)
| Parameters | Control Groups | Experimental Groups |
|---|---|---|
| t1/2 (hrs) | 4.56 ± 0.89 | 4.51 ± 0.69 |
| Tmax (hrs) | 1.33 ± 0.26 | 1.03 ± 0.27* |
| MRT(0-t) (hrs) | 6.28 ± 0.98 | 6.38 ± 0.57 |
| MRT(0-∞) (hrs) | 6.51 ± 1.17 | 6.61 ± 0.59 |
| Cmax (ng/mL) | 2253.80 ± 215.81 | 2721.37 ± 118.20* |
| CLz/F (L/h/kg) | 0.76 ± 0.16 | 0.59 ± 0.06* |
| AUC(0-t) (ng·h/mL) | 13,888.24 ± 2714.73 | 17,454.69 ± 1854.58* |
| AUC(0-∞) (ng·h/mL) | 13,974.99 ± 2784.04 | 17,539.44 ± 1894.29* |
Notes: Compared with venlafaxine group: *P<0.05.